Selvita（787）株式概要Selvita S.A.は世界的な開発業務受託機関として活動している。 詳細787 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長4/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より39.4%で取引されている 収益は年間42.28%増加すると予測されています リスク分析リスクチェックの結果、787 、リスクは検出されなかった。すべてのリスクチェックを見る787 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,064 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,064 investors already sharing narrativesYour Fair Value€Current Price€6.3471.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-5m548m2016201920222025202620282031Revenue zł547.5mEarnings zł69.4mAdvancedSet Fair ValueView all narrativesSelvita S.A. 競合他社EvotecSymbol: XTRA:EVTMarket cap: €612.5mPExASymbol: DB:FA0Market cap: €46.8mGerresheimerSymbol: XTRA:GXIMarket cap: €938.1mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €3.3b価格と性能株価の高値、安値、推移の概要Selvita過去の株価現在の株価zł6.3452週高値zł11.0552週安値zł5.51ベータ0.0841ヶ月の変化-3.79%3ヶ月変化-12.19%1年変化-13.39%3年間の変化-57.56%5年間の変化-60.42%IPOからの変化-48.66%最新ニュースお知らせ • Jun 01Selvita S.A., Annual General Meeting, Jun 24, 2026Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time.Reported Earnings • May 26First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025)First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.お知らせ • Nov 15Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025お知らせ • Aug 21Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025お知らせ • Dec 11Selvita Strengthens Management Structure in Sales and Drug Development SegmentSelvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets.Reported Earnings • Sep 27Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023)Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesお知らせ • Jun 01Selvita S.A., Annual General Meeting, Jun 24, 2026Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time.Reported Earnings • May 26First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025)First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.お知らせ • Nov 15Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025お知らせ • Aug 21Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025お知らせ • Dec 11Selvita Strengthens Management Structure in Sales and Drug Development SegmentSelvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets.Reported Earnings • Sep 27Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023)Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • May 23First quarter 2024 earnings released: zł0.12 loss per share (vs zł0.14 profit in 1Q 2023)First quarter 2024 results: zł0.12 loss per share (down from zł0.14 profit in 1Q 2023). Revenue: zł77.2m (down 16% from 1Q 2023). Net loss: zł2.14m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • May 08Selvita S.A. (WSE:SLV) acquired PozLab sp. z o.o from YouNick Mint Sp. z o.o.Selvita S.A. (WSE:SLV) agreed to acquire PozLab sp. z o.o from YouNick Mint Sp. z o.o. for PLN 25 million on March 27, 2024. The consideration PLN 21 million will be paid on the day of acquisition of the Shares and PLN 4 million will be retained by the Issuer for a period of up to 12 months from the date of closing the Transaction as security for any, specifically enumerated in the Agreement, events or claims by third parties against PozLab, as well as to secure settlements related to price adjustments. The acquisition of shares will be financed from the issuer's own funds. The Issuer will consider refinancing the Transaction with debt in the future. Upon the fulfillment of the following conditions: i) obtaining the consent of the National Centre for Research and Development (in Polish: Narodowe Centrum Badan i Rozwoju), granted in at least documentary form, for the acquisition of all Shares by the Issuer; and ii) completion of the capital restructuring process of the Seller's group by concluding, between PozLab and a third party designated by the Seller, an agreement for the sale of 100% of the shares in Applied Manufacturing Science sp. z o.o., a subsidiary of PozLab. The parties may agree on a different closing date. In the event of non-fulfillment of the Suspensive Conditions by September 30, 2024, the Issuer is entitled to withdraw from the Preliminary Agreement. In 2023, PozLab recorded revenues of PLN 15.3 million and estimated EBITDA of PLN 1.7 million. The completion of the transaction is dependent on obtaining consent from the National Centre for Research and Development for the acquisition. The transaction is expected to be closed on 30th business day. Selvita S.A. (WSE:SLV) completed the acquisition of PozLab sp. z o.o from YouNick Mint Sp. z o.o. on May 7, 2024.Reported Earnings • Mar 31Full year 2023 earnings released: EPS: zł3.80 (vs zł1.65 in FY 2022)Full year 2023 results: EPS: zł3.80 (up from zł1.65 in FY 2022). Revenue: zł351.9m (down 15% from FY 2022). Net income: zł69.9m (up 131% from FY 2022). Profit margin: 20% (up from 7.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Mar 19Selvita S.A. Launches Biologic Drug Discovery and Development ServicesSelvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped laboratories. As Selvita ventures into the dynamic field of biologic drug discovery, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery. Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years. Antibody discovery and development form the cornerstone of expansion into a comprehensive suite of services for biologics drug discovery and development. With biologics emerging as the fastest-growing sector within life sciences, recognize the immense potential of this strategic move. the company eagerly anticipate welcoming new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations. Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development. The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays. This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of "All Under One Roof" Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area. With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market.お知らせ • Jan 19+ 3 more updatesSelvita S.A. to Report First Half, 2024 Results on Sep 25, 2024Selvita S.A. announced that they will report first half, 2024 results on Sep 25, 2024Reported Earnings • Jun 04First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł91.8m (down 3.4% from 1Q 2022). Net income: zł2.59m (down 47% from 1Q 2022). Profit margin: 2.8% (down from 5.2% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Jun 02Selvita S.A., Annual General Meeting, Jun 27, 2023Selvita S.A., Annual General Meeting, Jun 27, 2023, at 11:30 Central European Standard Time.お知らせ • Jan 31+ 3 more updatesSelvita S.A. to Report Q3, 2023 Results on Nov 15, 2023Selvita S.A. announced that they will report Q3, 2023 results on Nov 15, 2023お知らせ • Nov 23Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million.Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: PLN 78.7Reported Earnings • Sep 17Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł103.4m (up 46% from 2Q 2021). Net income: zł3.80m (up zł4.10m from 2Q 2021). Profit margin: 3.7% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Jun 07Selvita S.A., Annual General Meeting, Jun 30, 2022Selvita S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł95.0m (up 35% from 1Q 2021). Net income: zł4.89m (down 48% from 1Q 2021). Profit margin: 5.2% (down from 13% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in Germany.Buying Opportunity • May 03Now 23% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be €20.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.Buying Opportunity • Apr 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €20.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.Reported Earnings • Apr 05Full year 2021 earnings released: EPS: zł0.81 (vs zł1.05 in FY 2020)Full year 2021 results: EPS: zł0.81 (down from zł1.05 in FY 2020). Revenue: zł315.7m (up 123% from FY 2020). Net income: zł14.9m (down 17% from FY 2020). Profit margin: 4.7% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany.Buying Opportunity • Feb 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be zł20.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years.お知らせ • Feb 02Selvita Announces Management ChangesSelvita informed about signing a preliminary contract to purchase another plot of land to expand its own laboratory space and secure further organic growth in Krakow, Poland. The integrated departments providing drug discovery services, operating in Krakow, Poznan, and Zagreb, will be led by Dr. Adrijana Vinter, who takes on a role of the Global Head of Drug Discovery and joins Selvita Management Board. Prior to that, for the past four years, Dr. Vinter has held the position of Managing Director at Fidelta. The Company intends to also integrate its business development and sales activities. Dr. Milosz Gruca, who will assume the position of Chief Commercial Officer, Executive Vice President, will be managing teams responsible for the development and sales of the integrated Selvita and Fidelta services offer in the area of drug discovery and development. Growing Group's scale of operations and its further development plans have led to creation of the Chief Operating Officer function, assumed by Dr. Miroslawa Zydron, the current Chemistry Department Director. Dr. Zydron will be responsible for the Group's operational activities, investments, and infrastructure management.Reported Earnings • Nov 25Third quarter 2021 earnings: Revenues exceed analyst expectationsThird quarter 2021 results: Revenue: zł81.5m (up 119% from 3Q 2020). Net loss: zł2.32m (down 153% from profit in 3Q 2020). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 30%, compared to a 32% growth forecast for the industry in Germany.Reported Earnings • Sep 23Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł70.8m (up 94% from 2Q 2020). Net loss: zł302.7k (down 106% from profit in 2Q 2020).Reported Earnings • May 30First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł70.3m (up 128% from 1Q 2020). Net income: zł9.37m (up 175% from 1Q 2020). Profit margin: 13% (up from 11% in 1Q 2020). The increase in margin was driven by higher revenue.株主還元787DE Life SciencesDE 市場7D3.9%1.4%0.2%1Y-13.4%6.7%3.6%株主還元を見る業界別リターン: 787過去 1 年間で6.7 % の収益を上げたGerman Life Sciences業界を下回りました。リターン対市場: 787は、過去 1 年間で3.6 % のリターンを上げたGerman市場を下回りました。価格変動Is 787's price volatile compared to industry and market?787 volatility787 Average Weekly Movement6.1%Life Sciences Industry Average Movement6.0%Market Average Movement5.2%10% most volatile stocks in DE Market13.0%10% least volatile stocks in DE Market2.7%安定した株価: 787 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 787の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2007899Boguslaw Sieczkowskiselvita.comセルヴィータ社は、世界的な医薬品開発業務受託機関として事業を展開している。AIを活用した創薬、抗体創薬、構造生物学、組換えタンパク質生産、アッセイ開発・スクリーニング、コンピューター支援薬物設計、医薬品化学・合成化学、スケールアップ、ADME/DMPK、in vitro・in Vivo薬理学、トランスレーショナルリサーチ、毒物学の分野で創薬サービスを提供している。また、がん、感染症、免疫学、神経学、呼吸器学などの治療分野向けの医薬品開発も行っている。さらに、製剤開発、CMC分析サポート、安定性および保存可能期間の決定、臨床供給/GMP製造、低分子バイオ分析、原薬および製品、生物製剤およびバイオシミラーのバイオ分析サービスを含む医薬品開発サービスを提供している。さらに、農薬分析サポート、フレーバー・フレグランスケミストリーの分野でも研究開発サービスを提供している。同社は以前Selvita CRO S.A.として知られていたが、2019年10月にSelvita S.A.に社名を変更した。Selvita S.A.は2007年に設立され、ポーランドのクラクフを拠点としている。もっと見るSelvita S.A. 基礎のまとめSelvita の収益と売上を時価総額と比較するとどうか。787 基礎統計学時価総額€121.47m収益（TTM）-€847.53k売上高(TTM)€83.45m1.5xP/Sレシオ-143.3xPER（株価収益率787 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計787 損益計算書（TTM）収益zł359.37m売上原価zł69.38m売上総利益zł290.00mその他の費用zł293.65m収益-zł3.65m直近の収益報告Mar 31, 2026次回決算日Sep 17, 2026一株当たり利益（EPS）-0.20グロス・マージン80.69%純利益率-1.02%有利子負債／自己資本比率28.8%787 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 18:01終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Selvita S.A. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Beata Szparaga-WasniewskaBiuro maklerskie mBankuSylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.Tomasz SokolowskiErste Bank Polska S.A.4 その他のアナリストを表示
お知らせ • Jun 01Selvita S.A., Annual General Meeting, Jun 24, 2026Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time.
Reported Earnings • May 26First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025)First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 15Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025
お知らせ • Aug 21Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025
お知らせ • Dec 11Selvita Strengthens Management Structure in Sales and Drug Development SegmentSelvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets.
Reported Earnings • Sep 27Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023)Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jun 01Selvita S.A., Annual General Meeting, Jun 24, 2026Selvita S.A., Annual General Meeting, Jun 24, 2026, at 11:30 Central European Standard Time.
Reported Earnings • May 26First quarter 2026 earnings released: zł0.30 loss per share (vs zł0.054 loss in 1Q 2025)First quarter 2026 results: zł0.30 loss per share (further deteriorated from zł0.054 loss in 1Q 2025). Revenue: zł80.0m (down 12% from 1Q 2025). Net loss: zł5.45m (loss widened 453% from 1Q 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 15Selvita S.A. to Report Q3, 2025 Results on Nov 20, 2025Selvita S.A. announced that they will report Q3, 2025 results on Nov 20, 2025
お知らせ • Aug 21Selvita S.A. to Report First Half, 2025 Results on Sep 18, 2025Selvita S.A. announced that they will report first half, 2025 results on Sep 18, 2025
お知らせ • Dec 11Selvita Strengthens Management Structure in Sales and Drug Development SegmentSelvita S.A. announced the hiring of Dr. Paul Overton as Chief Commercial Officer. Bringing over 25 years of expertise in the pharmaceutical, biotechnology and CRO industries, Dr. Overton has an impressive track recording of managing business development at companies such as Sygnature Discovery, Eurofins, Evotec and Aptuit. His career has been defined by driving global sales growth, forging strategic partnerships with biopharmaceutical companies, and steering dynamic, fast-growing organizations to success. Additionally, Dr. Milosz Gruca will assume the role of Global Head of Drug Development, where he will oversee the company's rapidly expanding drug development segment and the area of services dedicated to biologic drugs. The hiring of Dr. Paul Overton as Chief Commercial Officer reflects Selvita's commitment to enhancing its international business development efforts. During his career, he has been personally responsible for achieving sales targets of several hundred million euros per year, and has played instrumental roles in numerous M&A transactions. Dr. Overton specializes in sales development of dynamically growing companies and management of global sales teams. His experience and expertise spans supporting the development of new services, optimizing the operations of sales structures and building strategic partnerships with biopharmaceutical companies. As Chief Commercial Officer, Dr. Overton will be responsible for managing the international business development team and strengthening Selvita's sales activities. His extensive industry experience, international relationships and scientific profile, will support the Group's position and growth in global markets.
Reported Earnings • Sep 27Second quarter 2024 earnings released: zł0.55 loss per share (vs zł0.43 profit in 2Q 2023)Second quarter 2024 results: zł0.55 loss per share (down from zł0.43 profit in 2Q 2023). Revenue: zł80.9m (down 9.2% from 2Q 2023). Net loss: zł10.0m (down 227% from profit in 2Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • May 23First quarter 2024 earnings released: zł0.12 loss per share (vs zł0.14 profit in 1Q 2023)First quarter 2024 results: zł0.12 loss per share (down from zł0.14 profit in 1Q 2023). Revenue: zł77.2m (down 16% from 1Q 2023). Net loss: zł2.14m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • May 08Selvita S.A. (WSE:SLV) acquired PozLab sp. z o.o from YouNick Mint Sp. z o.o.Selvita S.A. (WSE:SLV) agreed to acquire PozLab sp. z o.o from YouNick Mint Sp. z o.o. for PLN 25 million on March 27, 2024. The consideration PLN 21 million will be paid on the day of acquisition of the Shares and PLN 4 million will be retained by the Issuer for a period of up to 12 months from the date of closing the Transaction as security for any, specifically enumerated in the Agreement, events or claims by third parties against PozLab, as well as to secure settlements related to price adjustments. The acquisition of shares will be financed from the issuer's own funds. The Issuer will consider refinancing the Transaction with debt in the future. Upon the fulfillment of the following conditions: i) obtaining the consent of the National Centre for Research and Development (in Polish: Narodowe Centrum Badan i Rozwoju), granted in at least documentary form, for the acquisition of all Shares by the Issuer; and ii) completion of the capital restructuring process of the Seller's group by concluding, between PozLab and a third party designated by the Seller, an agreement for the sale of 100% of the shares in Applied Manufacturing Science sp. z o.o., a subsidiary of PozLab. The parties may agree on a different closing date. In the event of non-fulfillment of the Suspensive Conditions by September 30, 2024, the Issuer is entitled to withdraw from the Preliminary Agreement. In 2023, PozLab recorded revenues of PLN 15.3 million and estimated EBITDA of PLN 1.7 million. The completion of the transaction is dependent on obtaining consent from the National Centre for Research and Development for the acquisition. The transaction is expected to be closed on 30th business day. Selvita S.A. (WSE:SLV) completed the acquisition of PozLab sp. z o.o from YouNick Mint Sp. z o.o. on May 7, 2024.
Reported Earnings • Mar 31Full year 2023 earnings released: EPS: zł3.80 (vs zł1.65 in FY 2022)Full year 2023 results: EPS: zł3.80 (up from zł1.65 in FY 2022). Revenue: zł351.9m (down 15% from FY 2022). Net income: zł69.9m (up 131% from FY 2022). Profit margin: 20% (up from 7.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 19Selvita S.A. Launches Biologic Drug Discovery and Development ServicesSelvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. The company will employ a highly proficient team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped laboratories. As Selvita ventures into the dynamic field of biologic drug discovery, it will offer a suite of fully comprehensive antibody-related services, encompassing a wide spectrum of activities essential for therapeutic antibody discovery. Selvita will open a new research site in Wroclaw, Poland, where it will rent over 400 sq m of laboratories along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years. Antibody discovery and development form the cornerstone of expansion into a comprehensive suite of services for biologics drug discovery and development. With biologics emerging as the fastest-growing sector within life sciences, recognize the immense potential of this strategic move. the company eagerly anticipate welcoming new colleagues and seamlessly integrating the Wroclaw site into Selvita's operations. Entering into the realm of biological drugs discovery and development not only marks a significant expansion for Selvita, but also paves the way for new markets and opportunities. By venturing into this new field, Selvita is poised to augment its existing portfolio of services in small molecules' discovery and development. The introduction of new services for biologics will also seamlessly complement Selvita's current offerings in the area of production of high-quality recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays. This strategic expansion enables Selvita to establish a truly comprehensive and competitive offer of "All Under One Roof" Protein Services, addressing the needs and expectations of its current and potential customers, and positioning itself as a partner of choice for companies looking for a high-quality service in this area. With an extensive range of capabilities covering both small molecules and biological drugs, Selvita is primed to meet diverse client needs and seize emerging opportunities in the rapidly evolving biological drugs market.
お知らせ • Jan 19+ 3 more updatesSelvita S.A. to Report First Half, 2024 Results on Sep 25, 2024Selvita S.A. announced that they will report first half, 2024 results on Sep 25, 2024
Reported Earnings • Jun 04First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł91.8m (down 3.4% from 1Q 2022). Net income: zł2.59m (down 47% from 1Q 2022). Profit margin: 2.8% (down from 5.2% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Jun 02Selvita S.A., Annual General Meeting, Jun 27, 2023Selvita S.A., Annual General Meeting, Jun 27, 2023, at 11:30 Central European Standard Time.
お知らせ • Jan 31+ 3 more updatesSelvita S.A. to Report Q3, 2023 Results on Nov 15, 2023Selvita S.A. announced that they will report Q3, 2023 results on Nov 15, 2023
お知らせ • Nov 23Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million.Selvita S.A. has completed a Follow-on Equity Offering in the amount of PLN 78.7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: PLN 78.7
Reported Earnings • Sep 17Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł103.4m (up 46% from 2Q 2021). Net income: zł3.80m (up zł4.10m from 2Q 2021). Profit margin: 3.7% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Jun 07Selvita S.A., Annual General Meeting, Jun 30, 2022Selvita S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time.
Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł95.0m (up 35% from 1Q 2021). Net income: zł4.89m (down 48% from 1Q 2021). Profit margin: 5.2% (down from 13% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in Germany.
Buying Opportunity • May 03Now 23% undervaluedOver the last 90 days, the stock is up 2.9%. The fair value is estimated to be €20.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.
Buying Opportunity • Apr 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €20.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 59% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings is also forecast to grow by 47% per annum over the same time period.
Reported Earnings • Apr 05Full year 2021 earnings released: EPS: zł0.81 (vs zł1.05 in FY 2020)Full year 2021 results: EPS: zł0.81 (down from zł1.05 in FY 2020). Revenue: zł315.7m (up 123% from FY 2020). Net income: zł14.9m (down 17% from FY 2020). Profit margin: 4.7% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany.
Buying Opportunity • Feb 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be zł20.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years.
お知らせ • Feb 02Selvita Announces Management ChangesSelvita informed about signing a preliminary contract to purchase another plot of land to expand its own laboratory space and secure further organic growth in Krakow, Poland. The integrated departments providing drug discovery services, operating in Krakow, Poznan, and Zagreb, will be led by Dr. Adrijana Vinter, who takes on a role of the Global Head of Drug Discovery and joins Selvita Management Board. Prior to that, for the past four years, Dr. Vinter has held the position of Managing Director at Fidelta. The Company intends to also integrate its business development and sales activities. Dr. Milosz Gruca, who will assume the position of Chief Commercial Officer, Executive Vice President, will be managing teams responsible for the development and sales of the integrated Selvita and Fidelta services offer in the area of drug discovery and development. Growing Group's scale of operations and its further development plans have led to creation of the Chief Operating Officer function, assumed by Dr. Miroslawa Zydron, the current Chemistry Department Director. Dr. Zydron will be responsible for the Group's operational activities, investments, and infrastructure management.
Reported Earnings • Nov 25Third quarter 2021 earnings: Revenues exceed analyst expectationsThird quarter 2021 results: Revenue: zł81.5m (up 119% from 3Q 2020). Net loss: zł2.32m (down 153% from profit in 3Q 2020). Revenue exceeded analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 30%, compared to a 32% growth forecast for the industry in Germany.
Reported Earnings • Sep 23Second quarter 2021 earnings releasedThe company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł70.8m (up 94% from 2Q 2020). Net loss: zł302.7k (down 106% from profit in 2Q 2020).
Reported Earnings • May 30First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł70.3m (up 128% from 1Q 2020). Net income: zł9.37m (up 175% from 1Q 2020). Profit margin: 13% (up from 11% in 1Q 2020). The increase in margin was driven by higher revenue.
